AU2003213168A1 - IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE - Google Patents

IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Info

Publication number: AU2003213168A1
Authority: AU; Australia
Prior art keywords: terminal cysteine; particles stabilized; hbc chimer; chimer particles; immunogenic
Prior art date: 2002-02-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003213168A

Other versions

AU2003213168A8 (en

Inventor

Ashley J. Birkett

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Apovia Inc

Original Assignee

Apovia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-21

Filing date

2003-02-21

Publication date

2003-12-19

2002-02-21 Priority claimed from US10/082,014 external-priority patent/US20030185858A1/en

2002-02-21 Priority claimed from US10/080,299 external-priority patent/US20030175863A1/en

2002-10-21 Priority claimed from US10/274,616 external-priority patent/US20030202982A1/en

2003-02-21 Application filed by Apovia Inc filed Critical Apovia Inc

2003-12-19 Publication of AU2003213168A8 publication Critical patent/AU2003213168A8/en

2003-12-19 Publication of AU2003213168A1 publication Critical patent/AU2003213168A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AU2003213168A 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE Abandoned AU2003213168A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US10/082,014 US20030185858A1 (en)	2001-08-15	2002-02-21	Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US10/080,299		2002-02-21
US10/080,299 US20030175863A1 (en)	2001-08-15	2002-02-21	Influenza immunogen and vaccine
US10/082,014		2002-02-21
US10/274,616		2002-10-21
US10/274,616 US20030202982A1 (en)	2001-08-15	2002-10-21	Influenza immunogen and vaccine
PCT/US2003/005196 WO2003102165A2 (en)	2002-02-21	2003-02-21	IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Publications (2)

Publication Number	Publication Date
AU2003213168A8 AU2003213168A8 (en)	2003-12-19
AU2003213168A1 true AU2003213168A1 (en)	2003-12-19

Family

ID=29715970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003213168A Abandoned AU2003213168A1 (en)	2002-02-21	2003-02-21	IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Country Status (3)

Country	Link
EP (1)	EP1517702A4 (en)
AU (1)	AU2003213168A1 (en)
WO (1)	WO2003102165A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7351413B2 (en) *	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
ES2555544T3 (en)	2006-03-07	2016-01-04	Vaxinnate Corporation	Compositions that include hemagglutinin, preparation methods and methods of use thereof
JP2009543554A (en)	2006-07-14	2009-12-10	サノフィパスツールバイオロジクスカンパニー	Construction of recombinant viral vaccines by direct transposon-mediated insertion of foreign immune determinants into vector viral proteins
CA2664791A1 (en)	2006-09-29	2008-08-21	Sanofi Pasteur Biologics Co.	Recombinant rhinovirus vectors
EP2185195A2 (en)	2007-08-16	2010-05-19	Tripep Ab	Immunogen platform
CN104080475A (en)	2008-04-18	2014-10-01	法克斯因内特公司	Deletion mutants of flagellin and methods of use
SG186611A1 (en)	2008-12-09	2013-01-30	Pfizer Vaccines Llc	Ige ch3 peptide vaccine
RU2518291C2 (en)	2009-07-30	2014-06-10	Пфайзер Вэксинс ЭлЭлСи	Antigen tau-peptides and their application
AU2010290931B2 (en)	2009-09-03	2014-02-06	Pfizer Vaccines Llc	PCSK9 vaccine
EP2942061A3 (en)	2010-06-07	2016-01-13	Pfizer Vaccines LLC	Ige ch3 peptide vaccine
WO2012131504A1 (en)	2011-03-02	2012-10-04	Pfizer Inc.	Pcsk9 vaccine
CN106279379B (en) *	2016-09-13	2020-05-22	华兰生物工程股份有限公司	Immunogen HM4-M2e, and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5143726A (en) *	1986-12-09	1992-09-01	The Scripps Research Institute	T cell epitopes of the hepatitis B virus nucleocapsid protein
KR100581991B1 (en) *	1998-02-12	2006-05-23	이뮨 컴플렉스, 코포레이션	Modified hepatitis V core protein and derivatives thereof
US5990085A (en) *	1998-05-04	1999-11-23	Michigan State University	Inhibin-HBc fusion protein
US20030138769A1 (en) *	2000-08-16	2003-07-24	Birkett Ashley J.	Immunogenic HBc chimer particles having enhanced stability

2003
- 2003-02-21 AU AU2003213168A patent/AU2003213168A1/en not_active Abandoned
- 2003-02-21 WO PCT/US2003/005196 patent/WO2003102165A2/en not_active Ceased
- 2003-02-21 EP EP03709214A patent/EP1517702A4/en not_active Withdrawn

Also Published As

Publication number	Publication date
AU2003213168A8 (en)	2003-12-19
WO2003102165A3 (en)	2005-01-06
WO2003102165A2 (en)	2003-12-11
EP1517702A2 (en)	2005-03-30
EP1517702A4 (en)	2006-05-03

Publication	Publication Date	Title
AU2003293294A1 (en)	2004-04-19	Uv-stabilised particles
AU2003301769A1 (en)	2004-06-07	Stabilized semiconductor nanocrystals
AU2003225031A1 (en)	2003-11-11	Eptfe-reinforced perfluoroelastomers
AU2003249646A1 (en)	2003-12-12	Metal implants with high porosity
AU2003233658A1 (en)	2003-12-12	Sulfonated carbonaceous materials
AU2002237315A1 (en)	2003-09-16	Atm-port-module with integrated ethernet switch interface
AU2002353921A1 (en)	2003-05-19	Proteins stabilized with polysaccharide gums
AU2003220410A1 (en)	2003-10-08	Airway assembly
AU2003213168A1 (en)	2003-12-19	IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
AU2003206862A1 (en)	2003-09-02	Hepatitis b vaccines
AU2003215395A1 (en)	2003-09-09	STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
AU2003242274A1 (en)	2004-01-06	Writing utensil
AU2003271536A1 (en)	2004-05-04	Menu choice
AU2003201888A1 (en)	2003-07-30	Resin particles
IL168106A0 (en)	2009-02-11	Stabilized, solid-state polypeptide particles
WO2004003149A8 (en)	2005-03-31	Cngh0005 polypeptides, antibodies, compositions, methods and uses
AU2003301316A1 (en)	2004-05-04	Improved immunotherapy
AU2003290012A1 (en)	2004-06-30	L2-peptide of the human papillomavirus associated with virus-like particles
AU2003249282A1 (en)	2004-02-02	Glanders/meliodosis vaccines
AU2003228863A1 (en)	2003-11-17	Immunogenic peptides
AU2002354197A1 (en)	2004-04-30	Fuel composition
GB0201382D0 (en)	2002-03-13	Virus-like particles
AU2003282350A1 (en)	2004-06-03	Chimeric autoprocessing polypeptides and uses thereof
AU2003202873A1 (en)	2003-07-24	Containers with additional functionality
AU2003277582A1 (en)	2004-06-07	Fluoropolymer

Legal Events

Date	Code	Title	Description
2004-11-04	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase